CytomX Therapeutics, Inc. (CTMX) Return on equity 2016–2025
CytomX Therapeutics, Inc. (CTMX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-17.5%FY2025 · since FY2016: -75.1% → -17.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -17.5% | — |
| FY2019 | -521.5% | -459.2 pp |
| FY2018 | -62.3% | -0.6 pp |
| FY2017 | -61.7% | +13.4 pp |
| FY2016 | -75.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice